Drug Discovery Services: Target Validation

Drug Discovery Services: Target Validation

Investigate the target’s potential as a drug using fresh patient tissue or patient-specific iPSC-derived disease model cells.

Assess the Efficacy of Your Drug Candidate in Diseased and Healthy Tissue

  • Compare activation of potential target and functional response.
  • Explore differences in drug response between patients and relate responses to clinical histories.
COPD lung Healthy lung
Find out more about our Target Validation services in functional human tissues »

Patient-specific iPS Cell generation service

Custom iPSCs can be created by reprogramming patient samples (Fibroblast, Blood, Urine, etc.) with Stemgent’s exclusive StemRNA-NM footprint-free RNA technology. Patient-specific iPSCs are a self-renewing and expandable cell population with potential to differentiate into virtually any cell type.

We also have the ability to provide precision genome-edited cells by working with our leading industry partners. The ability to model human diseases using iPSCs has revolutionized the ways in which we study monogenic, complex and epigenetic disorders, as well as early- and late-onset diseases.

Find out more about our iPSC reprogramming capabilities »

ReproCELL iPSC-derived Differentiated Cells

ReproCELL offers iPSC-derived differentiated cardiac cells, hepatocytes, and neurons suitable for use in basic research as model systems for a variety of applications. Unlike primary cells which may come from random donors with variable genetic backgrounds, these iPSC-derived cells have strong lot-to-lot performance consistency.

ReproCELL also has the ability to prepare customized versions of iPSC-derived cell types as required.

ReproCardio2™ ReproNeuro™ ReproHepato™
Find out more about ReproCardio2™ »

Find out more about ReproNeuro™ »

Find out more about ReproHepato™ »

Live chat by BoldChat